Akero Therapeutics, Inc. (AKRO)
NASDAQ: AKRO · Real-Time Price · USD
53.88
-0.20 (-0.37%)
At close: Oct 10, 2025, 4:00 PM EDT
53.86
-0.02 (-0.04%)
After-hours: Oct 10, 2025, 7:51 PM EDT
Akero Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts that cover Akero Therapeutics stock have a consensus rating of "Buy" and an average price target of $73.56, which forecasts a 36.53% increase in the stock price over the next year. The lowest target is $54 and the highest is $109.
Price Target: $73.56 (+36.53%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Akero Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 6 | 7 | 5 |
| Buy | 3 | 3 | 3 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 7 | 8 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Oct 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $72 → $54 | Strong Buy → Hold | Downgrades | $72 → $54 | +0.22% | Oct 10, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $75 → $56 | Strong Buy → Hold | Downgrades | $75 → $56 | +3.93% | Oct 9, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $73 → $54 | Strong Buy → Hold | Downgrades | $73 → $54 | +0.22% | Oct 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $72 | Strong Buy | Initiates | $72 | +33.63% | Sep 4, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.69
from -3.75
EPS Next Year
-4.33
from -3.69
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.76 | -4.07 | |||
| Avg | -3.69 | -4.33 | |||
| Low | -3.66 | -4.80 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.